Company intelligence / Profile preview

Verséa Ophthalmics

Tampa, Florida, United States

Ownership: Private
Development stage: Other

Overview

Verséa Ophthalmics commercializes tear-based point-of-care diagnostic tests and amnion-derived ocular allograft biologics (BIOVANCE and BIOVANCE 3L Ocular) for management of ocular surface diseases and surgical ocular wound healing, under an exclusive U.S. commercialization agreement with Celularity.

Therapeutic areas: Ophthalmology
Modalities: DeviceBiologic
Industry: Biotech

Partnerships

Celularity (exclusive U.S. commercialization agreement for BIOVANCE and BIOVANCE 3L Ocular allograft products)[2][8]AXIM Biotechnologies (commercial rights to ocular IgE, lactoferrin and MMP-9 diagnostic tests)[14]

Beyond the preview

Go deeper on Verséa Ophthalmics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verséa Ophthalmics.

Explore the full profile